

## Profile

**Dr. Thomas Tradler**  
**Head of Business Development / Patent**  
**Management,**  
**Fraunhofer Institute for Cell Therapy and**  
**Immunology (IZI), Leipzig, Germany**



Dr. Tradler has a scientific background in biochemistry. In 2001 and subsequent to an academic career at the Max-Planck-Society, he joined the pharmaceutical company Jerini AG in Berlin as a project leader. In this role he managed several preclinical or clinical drug development projects and was particularly involved in the development and successful market approval of Firazyr® (2008). Since 2009, Dr. Tradler held managerial positions in further IP asset management and biopharmaceutical companies.

In 2011, he joined the Fraunhofer Institute for Cell Therapy and Immunology, accepting a position as the Head of Business Development and Patent Management. Besides of being in charge of realizing a global business in joint development and contract research for biomedicine, Dr. Tradler particularly engaged to establish multiple collaborations with Canadian partners, culminating in the successful creation of the Fraunhofer Project Center for Biomedical Engineering and Advanced Manufacturing (BEAM) at McMaster University (Hamilton/Ontario) in 2014 that he managed as CEO from 2014 to 2016. In September 2016, Dr. Tradler entered the BEAM Supervisory Board. From April 2016 on, he also became a member of the board of the Center for Commercialization of Cancer Immunotherapy (C3i) in Montréal, Canada.